Today, inhibitors of EGFR, ALK, PI3K/AKT/mTOR, RAS-MAPK, RET, MET, BRAF, and NTRK/ROS1, as well as PD1 and CTLA4 molecules, are available for NSCLC, and many of these are now typical of care for selected patients (Fig. 1). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.